Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1385&sort=-program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=-program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1386&sort=-program_officials", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=-program_officials" }, "data": [ { "type": "Grant", "id": "9030", "attributes": { "award_id": "272201800013I-P00005-759302000002-1", "title": "Task V05: Development of Assays and Reagents for Coronavirus Vaccines", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-04-21", "end_date": "2022-04-30", "award_amount": 777134, "principal_investigator": { "id": 24843, "first_name": "THOMAS", "last_name": "RUDGE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through activities required for the submission of Biologic License Application (BLA) and/or Investigational New Drug (IND) applications. Task areas include: 1) administrative management and technical support including training and workshops, and quality oversight and management (site visits, critical stage audits, and final study report audits), 2) development, qualification and validation of immune assays, 3) immunogenicity and efficacy testing, 4) non-clinical and clinical sample testing, and 5) safety/toxicology studies. These services will facilitate the development and introduction of new vaccine candidates and biologics (regulated by CBER) against potential agents of bioterrorism and emerging and re-emerging infectious diseases.", "keywords": [ "2019-nCoV", "Area", "Biological", "Bioterrorism", "COVID-19", "COVID-19 vaccine", "Clinical", "Communicable Diseases", "Contracts", "Development", "Educational workshop", "Emerging Communicable Diseases", "Feasibility Studies", "Immunology procedure", "Investigational New Drug Application", "Licensing", "Office of Administrative Management", "Reagent", "Reporting", "Safety", "Sampling", "Services", "Site Visit", "Testing", "Toxicology", "Training", "Vaccines", "Validation", "assay development", "coronavirus vaccine", "efficacy testing", "evaluation/testing", "immunogenicity", "novel vaccines", "product development", "testing services", "vaccine candidate", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "9031", "attributes": { "award_id": "272201800013I-P00005-759302000002-2", "title": "Task V05: Development of Assays and Reagents for Coronavirus Vaccines", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-04-21", "end_date": "2022-04-30", "award_amount": 139564, "principal_investigator": { "id": 24843, "first_name": "THOMAS", "last_name": "RUDGE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through activities required for the submission of Biologic License Application (BLA) and/or Investigational New Drug (IND) applications. Task areas include: 1) administrative management and technical support including training and workshops, and quality oversight and management (site visits, critical stage audits, and final study report audits), 2) development, qualification and validation of immune assays, 3) immunogenicity and efficacy testing, 4) non-clinical and clinical sample testing, and 5) safety/toxicology studies. These services will facilitate the development and introduction of new vaccine candidates and biologics (regulated by CBER) against potential agents of bioterrorism and emerging and re-emerging infectious diseases.", "keywords": [ "2019-nCoV", "Area", "Biological", "Bioterrorism", "COVID-19", "COVID-19 vaccine", "Clinical", "Communicable Diseases", "Contracts", "Development", "Educational workshop", "Emerging Communicable Diseases", "Feasibility Studies", "Immunology procedure", "Investigational New Drug Application", "Licensing", "Office of Administrative Management", "Reagent", "Reporting", "Safety", "Sampling", "Services", "Site Visit", "Testing", "Toxicology", "Training", "Vaccines", "Validation", "assay development", "coronavirus vaccine", "efficacy testing", "evaluation/testing", "immunogenicity", "novel vaccines", "product development", "testing services", "vaccine candidate", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "9032", "attributes": { "award_id": "272201800013I-0-759302000002-1", "title": "Task V05: Development of Assays and Reagents for Coronavirus Vaccines", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-04-21", "end_date": "2022-04-30", "award_amount": 2950261, "principal_investigator": { "id": 24843, "first_name": "THOMAS", "last_name": "RUDGE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through activities required for the submission of Biologic License Application (BLA) and/or Investigational New Drug (IND) applications. Task areas include: 1) administrative management and technical support including training and workshops, and quality oversight and management (site visits, critical stage audits, and final study report audits), 2) development, qualification and validation of immune assays, 3) immunogenicity and efficacy testing, 4) non-clinical and clinical sample testing, and 5) safety/toxicology studies. These services will facilitate the development and introduction of new vaccine candidates and biologics (regulated by CBER) against potential agents of bioterrorism and emerging and re-emerging infectious diseases.", "keywords": [ "2019-nCoV", "Area", "Biological", "Bioterrorism", "COVID-19", "Clinical", "Communicable Diseases", "Contracts", "Coronavirus", "Development", "Educational workshop", "Emerging Communicable Diseases", "Feasibility Studies", "Immunology procedure", "Investigational New Drug Application", "Licensing", "Office of Administrative Management", "Reagent", "Reporting", "Safety", "Sampling", "Services", "Site Visit", "Testing", "Toxicology", "Training", "Vaccines", "Validation", "assay development", "efficacy testing", "evaluation/testing", "immunogenicity", "novel coronavirus", "novel vaccines", "product development", "testing services", "vaccine candidate", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "9033", "attributes": { "award_id": "272201800013I-P00003-759302000003-1", "title": "Task V06: Immunogenicity and efficacy testing of COVID-19 vaccine candidates in nonhuman primates", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-04-21", "end_date": "2024-04-30", "award_amount": 1064710, "principal_investigator": { "id": 24843, "first_name": "THOMAS", "last_name": "RUDGE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through activities required for the submission of Biologic License Application (BLA) and/or Investigational New Drug (IND) applications. Task areas include: 1) administrative management and technical support including training and workshops, and quality oversight and management (site visits, critical stage audits, and final study report audits), 2) development, qualification and validation of immune assays, 3) immunogenicity and efficacy testing, 4) non-clinical and clinical sample testing, and 5) safety/toxicology studies. These services will facilitate the development and introduction of new vaccine candidates and biologics (regulated by CBER) against potential agents of bioterrorism and emerging and re-emerging infectious diseases.", "keywords": [ "2019-nCoV", "Area", "Biological", "Bioterrorism", "COVID-19", "COVID-19 vaccine", "Clinical", "Communicable Diseases", "Contracts", "Development", "Educational workshop", "Emerging Communicable Diseases", "Feasibility Studies", "Immunology procedure", "Investigational New Drug Application", "Licensing", "Office of Administrative Management", "Reporting", "Safety", "Sampling", "Services", "Site Visit", "Testing", "Toxicology", "Training", "Vaccines", "Validation", "efficacy testing", "evaluation/testing", "immunogenicity", "nonhuman primate", "novel vaccines", "product development", "testing services", "vaccine candidate", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "9038", "attributes": { "award_id": "5U19AI149504-02", "title": "Modulation of repopulation of anti HIV-1 gene-modified cells to enhance efficacy and safety", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-05-07", "end_date": "2025-04-30", "award_amount": 466659, "principal_investigator": { "id": 22355, "first_name": "Dong Sung SUNG", "last_name": "An", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project 3: Summary/Abstract The overall goal of Project 3 is to modulate the levels of anti-HIV-1 chimeric antigen receptor (CAR) and broadly neutralizing antibodies (bNAb) modified immune cells by developing the most effective and safe positive and negative selection strategy to (1) achieve a therapeutic level of repopulation and (2) incorporate a safety “kill-switch” to eliminate the genetically engineered anti-HIV-1 immune effector cells in cases of unexpected adverse effects, such as cytokine storm, autoimmune reaction and malignant transformation. The hematopoietic stem cell-based gene therapy approach has shown great promise to achieve an HIV-1 cure. However, one of the major limitations has been the difficulty of achieving the engraftment levels sufficient to provide therapeutic efficacy, in particular for HIV-1 infected patients where intensive myeloablative conditionings would be an unfavorable risk-benefit. Thus, a safe and titratable positive selection strategy is highly desirable to maximize the level of anti-HIV-1 gene engineered immune cells to treat patients with HIV-1 without dangerous intensive myeloablation. Furthermore, it is important to incorporate a safety “kill-switch” procedure to eliminate the genetically engineered anti-HIV-1 immune effector cells based on lessons learned from severe adverse effects in cancer immunotherapy. Therefore, we will develop a negative selection strategy as a safety “kill-switch” to eliminate genetically engineered immune cells. We will identify the most effective and safe selection strategy from (1) knocking down hypoxanthine-guanine phosphoribosyltransferase (HPRT) expression using RNA interference that enables us to effectively enrich or eliminate anti-HIV-1 gene-modified HSPC using clinically available prodrug 6-thioguanine or methotrexate, (2) co-expressing truncated non-functional human epidermal growth factor receptor (huEGFRt), a cell surface marker for a rapid ex vivo positive selection and in vivo negative selection by an FDA-approved anti-EGFR monoclonal antibody Cetuximab (Erbitux) and (3) the P140K mutant form of human O6-methylguanine-DNA-methyltransferase (MGMTP140K) for a positive selection. We hypothesize that a clinically relevant, safe and effective positive and negative selection strategy can be developed by rigorously evaluating our proposed selection strategies for our anti-HIV-1 CAR and scFv-Fc bNAb combining therapies to achieve a cure of HIV disease.", "keywords": [ "Adverse effects", "Antigens", "Autoimmune", "B-Lymphocytes", "Benefits and Risks", "Bone Marrow Purging", "CAR T cell therapy", "CD19 gene", "Cell Count", "Cell surface", "Cells", "Cellular Immunity", "Cetuximab", "Clinical", "Clinical Trials", "Collaborations", "Comparative Study", "Dangerousness", "Disease", "Effector Cell", "Engineered Gene", "Engraftment", "Epidermal Growth Factor Receptor", "Erbitux", "FDA approved", "Gene Delivery", "Gene-Modified", "Genetic Engineering", "Goals", "HIV", "HIV-1", "Hematopoietic stem cells", "Human", "Humoral Immunities", "Hypoxanthine Phosphoribosyltransferase", "Immune", "In Vitro", "Investigational New Drug Application", "Lentivirus Vector", "MGMT gene", "Macaca nemestrina", "Malignant - descriptor", "Malignant Neoplasms", "Methotrexate", "Modeling", "Mus", "Patients", "Procedures", "Prodrugs", "RNA Interference", "Reaction", "Risk", "Safety", "T-Lymphocyte", "Testing", "Therapeutic", "Thioguanine", "TimeLine", "Toxic effect", "Transplantation", "Treatment Efficacy", "Virus Replication", "base", "cancer immunotherapy", "chimeric antigen receptor", "chimeric antigen receptor T cells", "clinically relevant", "cytokine release syndrome", "gene therapy", "immunoengineering", "immunogenicity", "in vivo", "knock-down", "mutant", "neutralizing antibody", "nonhuman primate", "preclinical development", "programs" ], "approved": true } }, { "type": "Grant", "id": "9039", "attributes": { "award_id": "75N91019D00024-P00002-759102000011-1", "title": "NIAID BIG EFFECT TRIAL (BET) FOR COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-05-01", "end_date": "2022-04-30", "award_amount": 24161705, "principal_investigator": { "id": 23486, "first_name": "BETH", "last_name": "BASELER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the Big Effect Trial (BET) to evaluate therapeutic agents against COVID-19.", "keywords": [ "COVID-19", "COVID-19 therapeutics", "Coronavirus", "National Institute of Allergy and Infectious Disease", "Therapeutic Agents", "therapeutic evaluation" ], "approved": true } }, { "type": "Grant", "id": "9047", "attributes": { "award_id": "75N92020P00132-P00004-0-1", "title": "THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION PERIOD 2 BY ADDING ADDING COVID-19 FUNDS FOR THE PERIOD OF PERFORMANCE OF 1/1/21 TO 4/30/21.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-05-08", "end_date": "2021-04-30", "award_amount": 2444259, "principal_investigator": { "id": 23973, "first_name": "MARK", "last_name": "MARINO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1670, "ror": "https://ror.org/00mgk5c15", "name": "VentureWell", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1670, "ror": "https://ror.org/00mgk5c15", "name": "VentureWell", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has an open solicitation for proposals to provide up to $500 million across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.", "keywords": [ "American", "COVID-19", "COVID-19 detection", "COVID-19 diagnostic", "COVID-19 testing", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Contracts", "Department of Defense", "Development", "Device Designs", "Diagnostic tests", "Ensure", "Exercise", "Exhalation", "Funding", "Goals", "Home", "Improve Access", "Laboratories", "Life Cycle Stages", "Modification", "National Institute of Biomedical Imaging and Bioengineering", "Patients", "Performance", "Point of Care Technology", "Privatization", "Program Development", "RADx", "Readiness", "Research", "Saliva", "Sampling", "Seasons", "Sensitivity and Specificity", "Speed", "Structure", "Technology", "Test Result", "Testing", "Time", "TimeLine", "United States National Institutes of Health", "Validation", "Virus", "base", "commercialization", "cost", "design", "detection limit", "flu", "handheld mobile device", "home test", "improved", "innovation", "meetings", "novel", "point of care", "product development", "programs", "scale up", "technology development", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "9055", "attributes": { "award_id": "5P20GM113123-05", "title": "Establishing Cellular Models of SARS-CoV2 Infection for COVID-19 Studies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-05-01", "end_date": "2021-08-04", "award_amount": 226172, "principal_investigator": { "id": 24779, "first_name": "Abraam M.", "last_name": "Yakoub", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 1728, "ror": "https://ror.org/04a5szx83", "name": "University of North Dakota", "address": "", "city": "", "state": "ND", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1728, "ror": "https://ror.org/04a5szx83", "name": "University of North Dakota", "address": "", "city": "", "state": "ND", "zip": "", "country": "United States", "approved": true }, "abstract": "Coronavirus Disease of 2019 (COVID-19) is a US and global public health crisis. It has led to the deaths of, at the point of writing this application, over 476,000 patients and 10 million infected individuals worldwide. The US was the most affected country, with over 123,000 deaths thus far and over 2.4 M infections. COVID-19 is caused by a novel beta-coronavirus (CoV) known as Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2), which was reported to cause severe pneumonia and lethal respiratory failure. There is no vaccine or FDA-approved drugs for COVID-19, and there is very little knowledge about this new virus at the basic science level. Thus, animal and cellular models are urgently needed to start to investigate the disease mechanism or test therapeutic interventions. Here, we propose to explore essential aspects of understanding COVID-19 viral infection: tissue tropism of the virus and antiviral innate immune responses of the host. Firstly, we will test viral tropism in various tissues relevant to reported COVID-19 symptoms and establish cellular models of the disease, by determining the expression of COVID-19 suggested entry receptor/cofactors, ACE2 and TMPRSS2, in various cell types and monitor the progress of infection over time using virus-specific assays and viral load quantification techniques. Secondly, we will test host cellular responses to SARS-CoV2 infection by determining the expression levels during infection, of proinflammatory cytokines and type-I interferons involved in antiviral defenses. We will also assess autophagy flux during infection, given that viruses gain growth advantage in cells by hijacking autophagy.", "keywords": [ "2019-nCoV", "Acute", "Affect", "Animal Model", "Animals", "Anti-Inflammatory Agents", "Antigen-Antibody Complex", "Antiviral Agents", "Autophagocytosis", "Bacteria", "Basic Science", "Biological Assay", "C Type Lectin Receptors", "COVID-19", "Cell model", "Cells", "Cessation of life", "Coronavirus", "Country", "Data", "Development", "Disease", "Disease model", "Equilibrium", "Event", "FDA approved", "Future", "Goals", "Growth", "Homeostasis", "Hospitalization", "Immune System Diseases", "Immune response", "Individual", "Infection", "Infection Control", "Infiltration", "Inflammation", "Inflammatory Response", "Innate Immune Response", "Integration Host Factors", "Interferon Type I", "Invaded", "Kinetics", "Klebsiella pneumoniae", "Knockout Mice", "Knowledge", "Lead", "Leukocytes", "Ligands", "Lower Respiratory Tract Infection", "Lung", "Mediating", "Modeling", "Molecular", "Monitor", "Mus", "Myeloid Cells", "Pathogenesis", "Pathologic", "Patients", "Pattern", "Pattern recognition receptor", "Phagocytes", "Phagocytosis", "Pharmaceutical Preparations", "Play", "Pneumonia", "Process", "Public Health", "Regulation", "Reporting", "Research", "Resolution", "Respiratory Failure", "Respiratory Tract Infections", "Role", "Sepsis", "Shapes", "Signal Transduction", "Symptoms", "TMPRSS2 gene", "Techniques", "Testing", "Therapeutic Intervention", "Tissues", "Tropism", "Tumor-infiltrating immune cells", "United States", "Vaccines", "Viral", "Viral Load result", "Virus", "Virus Diseases", "Writing", "antimicrobial", "cell type", "cofactor", "cytokine", "effective therapy", "immunoregulation", "mortality", "neutrophil", "novel", "pathogen", "prevent", "public health relevance", "receptor", "response", "septic", "therapeutic candidate", "therapeutic evaluation", "time use", "tissue tropism", "uptake", "virus tropism" ], "approved": true } }, { "type": "Grant", "id": "9058", "attributes": { "award_id": "75N93019C00015-P00001-9999-2", "title": "NIAID VIROLOGY QUALITY ASSURANCE (VQA) COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-06-21", "end_date": "2021-06-20", "award_amount": 668265, "principal_investigator": { "id": 24151, "first_name": "THOMAS", "last_name": "DENNY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "The purpose of the NIAID Virology Quality Assurance (VQA) program is to provide a comprehensive quality assessment program for virologic assays for HIV, and other viral pathogens, performed on samples from subjects enrolled in NIAID-sponsored multisite clinical studies. The VQA program ensures the validity and inter- and intra-laboratory comparability of virologic laboratory data obtained from NIAID-supported clinical trials and HIV natural history studies by providing laboratories with proficiency testing panels and real-time assay run controls and analyzing proficiency panel and assay run data from each laboratory. The VQA program also implements standards of performance for existing and state-of-the-art new virologic assays, develops and tests biostatistical methods relating to the assays, and acquires, tests, stores and dispenses quality control materials and reagents. Support under this project is for SARS-CoV-2 (COVID-19) virologic assay quality assurance activities.", "keywords": [ "2019-nCoV", "Biological Assay", "Biostatistical Methods", "Blood", "Blood specimen", "COVID-19", "Cells", "Clinical Trials", "Data", "Diagnosis", "Enrollment", "Ensure", "HIV", "Infection", "Inpatients", "Laboratories", "Methods", "Multi-site clinical study", "National Institute of Allergy and Infectious Disease", "Natural History", "Outpatients", "Patients", "Performance", "Plasma", "Quality Control", "Reagent", "Research", "Reverse Transcriptase Polymerase Chain Reaction", "Running", "Saliva", "Sampling", "Serum", "Site", "Swab", "Testing", "Time", "Tube", "Validation", "Viral", "Viral Load result", "Virus", "pathogenic virus", "programs", "quality assurance", "virology" ], "approved": true } }, { "type": "Grant", "id": "9075", "attributes": { "award_id": "75N92020P00146-P00012-0-1", "title": "TO MODIFY THE CONTRACT AND ADD ADDITIONAL FUNDING TO CONFIGURE A SMARTPHONE AND WEB-BASED DIGITAL HEALTH SOLUTION TO SUPPORT THE GENERAL PUBLIC USE OF", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-06-08", "end_date": "2022-06-07", "award_amount": 2358083, "principal_investigator": { "id": 24877, "first_name": "VIK", "last_name": "KHETERPAL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1793, "ror": "", "name": "CAREEVOLUTION, INC.", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1793, "ror": "", "name": "CAREEVOLUTION, INC.", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Institute of Biomedical Imaging and Bioengineering (NIBIB) requires a system that can be managed by a study team and that will support general public use of SARS-CoV-2 diagnostic tests performed in a home setting. The platform must be easily accessible on a mobile device, support a variety of surveys, display test-specific usage instructions, provide guidance to the user on actions to take following test results, provide reminder notifications for test frequency, record the test results, integrate with technologies that provide test interpretation (as available), and report results to public health authorities as applicable and authorized by the user. It must additionally make all these data available to the study team for future analysis, when this is within the remit of the IRB approval for the study.", "keywords": [ "Apple", "COVID-19 diagnostic", "Cellular Phone", "Clinical Trials", "Communication", "Communities", "Contractor", "Contracts", "Custom", "Data", "Data Collection", "Data Storage and Retrieval", "Diagnostic tests", "Enrollment", "Ensure", "Event", "Feedback", "Focus Groups", "Frequencies", "Funding", "Future", "General Population", "Health Services Accessibility", "Home", "Individual", "Institutional Review Boards", "Instruction", "Internet", "Language", "Manuals", "Market Research", "National Institute of Biomedical Imaging and Bioengineering", "Notification", "Observational Study", "Online Systems", "Participant", "Personal Health Records", "Play", "Privacy", "Public Health", "Reaction", "Readability", "Reporting", "Secure", "Specific qualifier value", "Surveys", "Symptoms", "System", "Technology", "Test Result", "Testing", "Time", "Vaccination", "authority", "base", "diaries", "digital", "digital health", "handheld mobile device", "home test", "repository" ], "approved": true } } ], "meta": { "pagination": { "page": 1385, "pages": 1419, "count": 14184 } } }